Monitoring TTO metrics is like a check-up with a doctor. When a physician measures your vitals, they’re not capturing a complete picture of your health. They’re checking a small set of high-signal indicators that provide a reliable snapshot of how your body is currently functioning. Weight, blood pressure, heart rate, and cholesterol can be fairly benign on their own. But when considered together, they tell a great deal about your chances at longevity or whether you should start cutting down on those donuts.
Technology transfer offices have never lacked for data. What they’ve lacked is data that answers the questions leadership is now asking. Ask any TTO director what they track, and you’ll almost certainly hear the same short list: invention disclosures, patents filed, licenses signed, revenue received. These are the metrics that national surveys ask for, that peer institutions report, and that have accumulated decades of historical momentum. They’re also, in many cases, the metrics that are easiest to count rather than the ones most useful to act on.
That’s not a criticism. But the pressure is real and building. TTO leaders tell us that they have to show impact, not just activity. The old activity-based metrics weren’t designed to answer that demand, and they’re starting to show their limits.
There’s a useful place to look for inspiration: the corporate innovation management world. Large R&D organizations have spent decades wrestling with the same fundamental problem: how do you measure something that is inherently unpredictable, spans organizational boundaries, and takes years to produce meaningful outcomes? They haven’t solved it completely, but they’ve built a practical toolkit of KPIs that go well beyond simple activity counts.
We have adapted that toolkit for the TTO context. For each of the eight KPIs below, we’ll identify the corporate innovation management equivalent, explain how it translates into a university tech transfer setting, describe what it actually tells you, and what to do about it. Crucially, almost all of the underlying data you’ll need already lives in your technology transfer management system. This isn’t about building new data infrastructure. It’s about asking better questions of the records you already keep.
Why TTO Metrics Are So Hard to Track
Before getting into the KPIs themselves, it’s worth naming the challenges honestly. If measuring technology transfer performance feels harder than measuring sales performance or marketing performance, that’s because it genuinely is for reasons that are structural, not organizational.
It’s hard to define what success looks like. Most business functions have a clear north star: revenue, cost reduction, headcount. Technology transfer doesn’t. Is a successful TTO one that files the most patents? Signs the most licenses? Creates the most spinouts? Generates the most income? Has the broadest faculty engagement? Produces the greatest societal impact? All of these are legitimate measures of success, and different stakeholders will weigh them very differently. Without clarity on what you’re actually trying to achieve, any measurement framework is built on shaky ground.
The timeline is non-linear and very long. A disclosure filed today may not generate its first licensing revenue for five to 10 years. A spinout formed this year may not become a meaningful employer for a decade after that. The connection between inputs and outputs in technology transfer is loose and delayed in ways that make standard annual performance metrics deeply misleading. You can have an excellent year of disclosures followed by a quiet year of licenses, with no causal relationship between the two.
Easy metrics aren’t always helpful metrics. There’s a well-known dynamic in any measurement system: you get what you measure. If your primary KPI is invention disclosures, you will, consciously or not, optimize for invention disclosures. That may mean encouraging faculty to submit disclosures that aren’t genuinely ready for commercialization, filling the pipeline with quantity rather than quality. The metrics that are easiest to count are often the ones most susceptible to this kind of distortion.
Outputs and outcomes are not the same thing. A license agreement executed is not a product on the market. A spinout incorporated is not a company that will survive to Series A. National surveys and annual reports tend to capture outputs (the formal transactions a TTO completes) but the outcomes those transactions produce are harder to track and often only become visible years later. Building a metrics framework that reaches toward outcomes, not just outputs, requires patience and a longer institutional memory than most reporting cycles allow.
These aren’t excuses not to measure. They’re reasons to measure with more intention.
How to Build Your TTO Metrics Framework
The good news: none of those challenges require a new database or a bigger team to address. They require a smarter set of questions organized around three domains of health that corporate innovation leaders have used for years and that translate directly to the TTO context. Think of it as a set of vital signs for your office: not a complete diagnostic, but a reliable snapshot of how the system is functioning right now.
A TTO metrics framework works the same way. Rather than trying to measure everything, the goal is to identify a small set of well-chosen indicators that give reliable signals about the health of the system as a whole. Get them right, and you’ll know where to look when something needs attention.
The following eight KPIs are organized around three health domains that map closely to how corporate innovation leaders think about their own innovation systems:
- Portfolio health — Is the output of your commercialization activity valuable and strategically coherent? Are you generating real returns from the IP and spinouts your office manages?
- Pipeline health — Is the process working efficiently? Are opportunities moving through your stage gates at the right pace, and is the front end of the funnel generating enough quality input?
- System health — Is the broader environment functioning well? Are the right people engaged? Are decisions being made at the right points?
These three domains aren’t independent. A pipeline bottleneck will eventually show up in portfolio value, and low faculty engagement will eventually show up in a declining disclosure rate. But keeping them conceptually separate helps you diagnose where a problem is actually originating, rather than just where it’s showing up.
One important practical note before getting into the KPIs: you don’t need to implement all eight at once, and you probably shouldn’t. The most useful starting point is to identify which domain represents your most pressing current concern and focus there first; the fastest route to metric overload is trying to run all three simultaneously. A TTO that is confident in its portfolio value but worried about process efficiency should start with the pipeline health metrics. One that has strong pipeline activity but is struggling to demonstrate value to university leadership should start with portfolio health. System health metrics tend to be most useful as a diagnostic when the other two domains look unexpectedly weak.
The 8 KPIs for Measuring TTO Success
Portfolio Health
1. Portfolio Value
Corporate analog: Product Portfolio NPV
What it measures: The aggregate current value of your commercialization portfolio: the total of what your office’s activities have produced and are producing.
How to calculate it: At its most straightforward, portfolio value is the sum of total annual license income, the current estimated equity value of shares held in university spinouts, investment raised by those spinouts during the year (a useful proxy for third-party validation of their value), and income from commercial R&D and collaborative research agreements.
For a more sophisticated version, you can begin modeling future income streams from active licenses, projecting out royalty flows as licensed products reach market and revenues grow, then discounting those back to a present value. This forward-looking approach is more demanding to build, but it produces something much more useful than a backward-looking income figure: a tool for scenario planning. Are you approaching a patent cliff of several major licenses expiring in the same window with insufficient pipeline to replace them? Modeling these dynamics gives you the evidence base to make the case to university leadership for investment before the problem arrives, rather than after.
Why it matters: Portfolio value is the closest thing the TTO has to a P&L. It answers the question that funders, university leadership, and government stakeholders are increasingly asking: what is the return on the institution’s investment in technology transfer? Activity-based metrics can’t answer that question. This one can, or at least gets you much closer.
2. Commercialization Conversion Rate
Corporate analog: R&D-to-Product Conversion
What it measures: How effectively your TTO converts raw research output into commercial activity at each stage of the process.
How to calculate it: This is a pipeline-stage analysis expressed as a series of conversion percentages: What share of invention disclosures lead to a provisional patent filing? Of those provisionals, what share progress to international filing? Of those, what share are ultimately granted? Of granted patents, what share are licensed? You can add further stages (such as what share of licenses generate active royalty income?) depending on how far downstream your tracking systems reach.
To make this meaningful for benchmarking, whether against your own historical performance or against peer institutions, normalize the input figure by research expenditure or by the number of research-active faculty. Raw disclosure counts reflect institutional size as much as TTO effectiveness; normalized rates reflect the productivity of the system.
Why it matters: Conversion rate analysis does something that counting outputs alone cannot: it shows you where attrition is happening. A TTO with a high disclosure rate and a low patent filing rate has a different problem than one with a high filing rate and a low licensing rate. The former may need better triage at the front end; the latter may need stronger marketing capability or more industry relationships. The metric doesn’t just describe performance, it points toward where intervention is most likely to have an effect.
3. Weighted Pipeline Risk Profile
Corporate analog: Weighted Average Portfolio Risk Score
What it measures: The overall risk balance of your active opportunity portfolio — whether you have a healthy spread of opportunities at different stages of development, or whether your portfolio is dangerously concentrated at the early, high-risk end.
How to calculate it: Map your active opportunities across your stage gates, and layer in technology readiness level (TRL) and commercial readiness level (CRL) scores for each. A portfolio weighted toward later-stage opportunities with higher TRL and CRL scores carries lower aggregate risk than one where most of the active inventory is at the early disclosure or evaluation stage. Some offices assign a simple risk score (high/medium/low) to each opportunity and track the weighted average across the portfolio over time.
Why it matters: TTOs don’t control their research inputs the way a corporate R&D team does. You can’t commission lower-risk research to balance an over-extended portfolio. But you can make conscious decisions about which early-stage opportunities to actively invest in marketing and IP protection, and which to monitor more lightly until the underlying technology matures. Understanding your portfolio’s risk profile gives you the basis for those decisions, and it’s a credible way to communicate with university leadership about why a period of low licensing income doesn’t necessarily indicate a failing TTO. It may simply reflect a portfolio that is heavily weighted toward longer-horizon opportunities.
Pipeline Health
4. Invention Disclosure Rate
Corporate analog: Idea Generation Rate
What it measures: The rate at which research-active faculty are bringing new inventions to the TTO’s attention, which is the fundamental input to the entire commercialization process.
How to calculate it: The raw metric is straightforward: number of invention disclosure forms received per year. As with commercialization conversion rate (above), the more useful figure for trend analysis and benchmarking is normalized: disclosures per $10 million of research expenditure, or disclosures per 100 research-active faculty members.
Where this metric becomes genuinely powerful is when it’s disaggregated. Overall disclosure rates can look healthy while masking significant imbalances: a handful of highly productive departments carrying the load while others contribute almost nothing, or a declining rate in a historically productive school that hasn’t yet shown up in the aggregate figure.
Why it matters: Disclosure rate is the leading indicator for everything that follows. A sustained decline in disclosures today means a thinner licensing pipeline in three to five years. Tracking this metric consistently and disaggregating it by school and department gives you advance warning of problems and a clear target for outreach activity. It also gives you a concrete way to measure whether faculty engagement initiatives are actually working, which feeds directly into the system health metrics later in this list.
5. Time Through Stage of Commercialization
Corporate analog: Time to Market / Days Over Launch
What it measures: How long it takes opportunities to move through your commercialization process, and whether that timing is consistent with the targets your office has set.
How to calculate it: This KPI has two complementary lenses that are best tracked together.
The first is average time: how long does it take, on average, to move from invention disclosure to a signed license or spinout formation? How long from license execution to first revenue? These averages give you a baseline for capacity planning and a benchmark for future comparison.
The second is lag rate: what percentage of active opportunities are taking longer than your internal commercialization stage targets? This requires you to have set those targets explicitly — which is itself a valuable exercise — and to be tracking actual progression dates against them in your management system. The lag rate surfaces bottlenecks and stalled opportunities that the average-time figure can obscure.
Why it matters: These two measures together tell you not just how fast your pipeline moves, but whether it moves consistently. A TTO with a fast average time but a high lag rate has a bimodal pipeline: most things move quickly, but a tail of opportunities is stuck and consuming disproportionate attention. A TTO with a slow average time but a low lag rate may simply be handling complex, long-horizon opportunities that require that time. It’s also worth distinguishing between an opportunity that’s drifting (no one’s actively managing it) and one that’s deliberately parked while the underlying science catches up to commercial readiness. The former is a resource drain; the latter is sound judgment. Your stage-gate data should let you tell the difference.
There’s also a reputational dimension here that’s worth naming. Surveys of academics consistently show that slow responsiveness is one of the most common complaints about tech transfer offices. If you have explicit stage-gate time targets and you track performance against them, you have evidence (not just reassurance) to offer when that perception arises. And if the data shows the complaint is partly justified, you know where to focus.
System Health
6. IDF Rejection Rate
Corporate analog: Idea Kill Rate
What it measures: The percentage of invention disclosures that are reviewed and then not taken forward to active commercialization.
How to calculate it: Disclosures not progressed to commercialization ÷ total disclosures received, over a defined period. Track this as a trend over time rather than as a point-in-time snapshot.
Why it matters: This is a metric that makes some TTO professionals uncomfortable because “rejection rate” sounds like failure. It isn’t. In the corporate innovation world, a healthy idea kill rate is considered a sign of a well-functioning system: it means the organization is doing rigorous triage, not investing resources in ideas that don’t justify the cost. The same logic applies in tech transfer. If your IDF rejection rate is zero (or close to it) it suggests that every disclosure is being taken forward regardless of commercial merit, which is almost certainly not an efficient use of patenting budget or commercialization capacity.
The question isn’t whether your rejection rate is high or low in absolute terms; it’s whether the rate is appropriate given your institutional context, and whether it’s moving in the right direction. If you’re just beginning to track this metric or introducing formal evaluation criteria for the first time, it’s also worth knowing what to expect. When a TTO begins applying consistent triage criteria to incoming disclosures, rather than defaulting to advancing everything, the rejection rate will typically spike in the first cycle as the backlog of underqualified IDFs is cleared. That’s not a sign of failure; it’s the portfolio correcting itself. Over time, as faculty understand what the TTO is looking for and submit more commercially considered disclosures, the rejection rate tends to stabilize or even fall below its pre-discipline baseline. That trajectory — up, then down — is the healthy pattern.
A rising rate of deciding not to proceed with an IDF may mean better triage or a declining quality of disclosures coming in, which points back to the disclosure rate and faculty engagement metrics for diagnosis.
7. Opportunity Abandonment Rate
Corporate analog: Product Kill Rate
What it measures: The percentage of opportunities that have progressed to active marketing or commercialization but do not ultimately result in a license or spinout.
How to calculate it: Opportunities abandoned after active commercialization ÷ total opportunities that entered active commercialization, over a defined period.
Why it matters: Where the IDF rejection rate measures triage at the front of the funnel, opportunity abandonment rate measures decision quality further downstream. Some abandonment is inevitable and healthy because market conditions change, the technology doesn’t develop as expected, or the right partner doesn’t materialize. What you’re watching for is the pattern and the pace.
Fast, deliberate abandonment — making a clear-eyed call that an opportunity isn’t going to succeed and reallocating resources accordingly — is good portfolio management. What erodes TTO effectiveness is slow, ambiguous abandonment: opportunities that are nominally active but receiving little real attention, consuming database entries and staff bandwidth without realistic prospect of a deal. Tracking abandonment rate, and the time elapsed before abandonment decisions are made in particular, helps surface this pattern and creates the organizational permission to make cleaner decisions earlier.
8. Faculty Engagement Rate
Corporate analog: Senior Leadership Innovation Mix / Employee Innovation Mix
What it measures: The proportion of research-active faculty who have meaningfully engaged with the TTO within a defined rolling period, whether by submitting a disclosure, attending an event, participating in a partnership discussion, or other tracked interaction.
How to calculate it: Faculty with at least one recorded TTO interaction in the past 12 or 24 months ÷ total research-active faculty. Segment by seniority, department, and school to identify where engagement is strong and where it is thin.
Why it matters: This is the most explicitly cultural metric on the list, and in some ways the most important. Every other metric in this framework is downstream of faculty engagement. If faculty don’t bring disclosures to the TTO, there’s no pipeline. If they don’t trust the TTO to handle their IP well, they’ll find other routes to commercialization or none at all.
A low or declining engagement rate is rarely primarily an IP problem. It’s almost always a relationship and communication problem with faculty who don’t know what the TTO offers, who’ve had a frustrating experience in the past, or who don’t see technology transfer as relevant to their work. Tracking engagement rate by department gives you a concrete, actionable map of where outreach effort is most needed. Tracking it over time gives you a way to measure whether that effort is working.
The segmentation by seniority, borrowed from the corporate metric’s distinction between senior leadership and employee engagement, is particularly useful. Senior faculty who are actively engaged with the TTO tend to normalize engagement for their departments. Their involvement is both a signal of institutional legitimacy and a practical source of referrals from junior colleagues.
Putting It Into Practice
Eight KPIs is still eight KPIs. If none of these are currently part of your measurement practice, trying to implement all of them simultaneously is a recipe for the metric overload that tends to crowd out the actual work of commercialization. A more practical approach is to let the three-domain structure guide your starting point. Which domain represents your most pressing current challenge?
If your TTO is under pressure to demonstrate its value to university leadership or government funders, start with portfolio health. Portfolio Value and Commercialization Conversion Rate together make a compelling, evidence-based case for what your office contributes, and they do so in language that leadership already understands.
If your concern is operational (opportunities moving too slowly, resources stretched unevenly, faculty complaining about responsiveness) start with pipeline health. Time Through Stage Gates in particular tends to generate immediate, actionable insight, and the process of setting explicit stage-gate targets is itself a valuable internal exercise.
If your disclosure pipeline is healthy and your deals are getting done, but you’re worried about the longer-term sustainability of the system (whether you’re building deep enough faculty relationships, or whether you’re making clean enough decisions on which opportunities to pursue) start with system health.
Finally, it’s worth noting that every KPI in this framework can be extended beyond the tech transfer office as universities move toward more integrated approaches to knowledge exchange and innovation impact. The same logic that applies to invention disclosures and licenses applies to collaborative research agreements, consultancy arrangements, and entrepreneurship programs. The framework scales; what matters is building the habit of measurement and using it to drive decisions rather than just to compile reports.
Create a Culture of Impact
Evolve is designed to be the system of record that makes metrics like these possible, tracking opportunities through every stage gate, recording the interactions and timelines that feed these calculations, and making the data accessible for reporting and analysis.
If you’re a tech transfer professional or institutional leader looking to modernize your workflows, streamline operations, and make a greater impact despite less resources, book a demo to see how your existing data can be put to work.